Company intelligence / Profile preview

CarbGeM

Shibuya-ku, Tokyo, Japancarbgem.com ↗

Ownership: Private
Development stage: Commercial

Overview

CarbGeM has developed AI-powered platforms—BiTTE and CarbConnect—for rapid bacterial identification and antimicrobial susceptibility guidance. These tools aim to improve early diagnosis, optimize antibiotic use, and combat antimicrobial resistance. BiTTE is under development with academic partners and preparing for regulatory approval in Japan; field testing is ongoing in Vietnam with plans to expand into other emerging markets.

Therapeutic areas: Infectious Diseases
Modalities: DeviceSoftware
Industry: Digital Health Medical Devices

Drug pipeline

3 assets

BiTTE-Urine

Commercial

Indications: Bacterial infection identification

2 more assets in the full pipeline.

Request access →

Partnerships

National Center for Global Health and Medicine, JapanKobe University

Beyond the preview

Go deeper on CarbGeM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CarbGeM.

Explore the full profile